Aggarwal C, Martinez-Marti A, Majem M, Barlesi F, Carcereny E, Chu Q, Monnet I, Sánchez-Hernández A, Dakhil S, Camidge DR, Pillet M, Brown M, Paliompeis C, Dowson A, Cooper ZA, Kumar R, Herbst RS. Durvalumab Alone or Combined With Novel Agents for Unresectable Stage III Non-Small Cell Lung Cancer: Update From the COAST Randomized Clinical Trial , JAMA Netw Open, 8: 2025,e2518440
Mack PC, Redman MW, Tukachinsky H, Kozono DE, Minichiello K, Dragnev KH, Tolba KA, Neal JW, Madison RW, Waqar SN, Aggarwal C, Hirsch FR, Patel JD, Herbst RS, Chiang AC, Reckamp KL, Kelly K, Borghaei H, Gray JE, Gandara DR. Elevated ctDNA Tumor Fraction Is Associated with Improved Mutation Detection but Worse Overall Survival in Advanced Non-Small Cell Lung Cancer: a Lung-MAP Study , Clin Cancer Res: 2025
Roy AM, Bakouny Z, Dizman N, Paul MA, Ozay ZI, Lal BM, Nawfal R, Eid M, Chehade REH, Machaalani M, Butt A, Aggarwal C, Bekaii-Saab T, Chavez-MacGregor M, Lopes G, Marshall AL, Murphy M, Owonikoko T, Xie W, Lee AI, Choueiri TK. International Medical Graduates Representation at International Oncology Conference Meetings: An Analysis of ASCO Annual Meetings , JCO Oncol Pract: 2025
Teja Voruganti, Rosalyn Marar, Benjamin Bleiberg, Edoardo Garbo, Biagio Ricciuti, Kaushal Parikh, Charu Aggarwal Perioperative Therapy in Oncogene-Driven Non–Small Cell Lung Cancer: Current Strategies and Unanswered Questions , American Society of Clinical Oncology Educational Book, 45(3): 2025
Kamboj M, Kirkwood MK, Bohlke K, Gralow JR, Garrett-Mayer E, Aggarwal C. More Frequent than Annual Administration of COVID-19 Vaccination May Be Appropriate for Patients With Cancer , JCO Oncol Adv, 2: 2025,e2400107
Cantor DJ, Nimeiri H, Horn L, West M, Ben-Shachar R, Huerga I, Patel JD, Aggarwal C. Outcomes Following First-Line Immune Checkpoint Inhibitors With or Without Chemotherapy Stratified by KRAS Mutational Status-A Real-World Analysis in Patients With Advanced NSCLC , Clin Lung Cancer: 2025
Adam Barsouk, Omar Elghawy, Alex Watts, Lauren Reed-Guy, William Tompkins, Krishna Chandrasekhara, Connor B Grady, Wade Iams, Fangdi Sun, Geoffrey Liu, Devalben Patel, Jorge J Nieva, Kristen A Marrone, Vamsidhar Velcheti, Stephen V Liu, Tejas Patil, Jared Weiss, William Schwartzman, Liza C Villaruz, Amanda Hermann, Dara L Aisner, Wei-Ting Hwang, D Ross Camidge, Lova Sun, Aditi Puri Singh, Roger B Cohen, Charu Aggarwal, Corey J Langer, Melina E Marmarelis Osimertinib vs. Afatinib in 1L therapy of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC): A multi-institution, real-world survival analysis , Lung Cancer, 203: 2025
Sun L, Marmarelis ME, Aggarwal C. Management of Patients With EGFR Exon 20-Mutant Advanced Non-Small Cell Lung Cancer , Journal of Clinical Oncology: 2025
Stalker M, Marmarelis M, Langer C, Cohen RB, Singh A, Aggarwal C, Sun L. Outcomes Following Treatment for Progression in Patients Treated With Durvalumab Consolidation in LA-NSCLC , Clin Lung Cancer, 26(2): 2025,124-130
Elghawy O, Barsouk A, Reed-Guy L, Stalker M, Sussman J, Robinson K, Kosteva J, Singh A, Cohen RB, Langer C, Ciunci C, D'Avella C, Sun L, Marmarelis ME, Aggarwal C. Brief Report: Osimertinib Plus Capmatinib for Patients With MET-Altered EGFR-Mutant NSCLC Following Progression on Front Line Therapy , Clin Lung Cancer, 26(2): 2025,158-163
